Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Philadelphia Chromosome 1Neoplasm, Residual 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 21Cytarabine 15blinatumomab 13fludarabine 12Azacitidine 10venetoclax 9fludarabine phosphate 9Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Rituximab 6Mercaptopurine 6Daunorubicin 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Etoposide 4Busulfan 4obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm, Residual × flumatinib × Clear all
NCT04375683 2022-03-24

Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

Zhongda Hospital

Phase 3 Unknown
28 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡